Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of 13.89% and 110.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug/Biotech Stock Q2 Earnings on Aug 5: REGN, MRNA & More

by Kinjel Shah

Let us take a look at five drug/biotech companies, REGN, MRNA, SRPT, ACAD and HZNP, which are gearing up for their earnings release.

Sweta Killa headshot

5 Growth ETFs & Stocks to Ride the Market Rally

by Sweta Killa

Growth investing has taken the lead over value and is likely to stay given a slew of reasons.

Zacks Equity Research

Ligand (LGND) Beats on Q2 Earnings & Sales, Raises View

by Zacks Equity Research

Ligand (LGND) reports better-than-expected second-quarter 2020 earnings and revenues. Stock up.

Ritujay Ghosh headshot

Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials

by Ritujay Ghosh

Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.

Sanghamitra Saha headshot

Top ETF Stories of July

by Sanghamitra Saha

Wall Street has been steady in July despite the rise in coronavirus cases due to fiscal and monetary stimulus, coronavirus vaccine hopes, pent-up consumer demand and decent earnings releases.

Zacks Equity Research

Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up

by Zacks Equity Research

Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.

Zacks Equity Research

Coronavirus Vaccine Efforts Key to Moderna (MRNA) Q2 Earnings

by Zacks Equity Research

Moderna (MRNA) is progressing with coronavirus vaccine development. The company has initiated a late-stage study and investors will likely focus any preliminary data from the study

Zacks Equity Research

AstraZeneca (AZN) Q2 Earnings & Sales Beat, Increase Y/Y

by Zacks Equity Research

AstraZeneca (AZN) comes up with better-than expected Q2 results. It maintains its financial outlook for the year. Stock up.

Zacks Equity Research

Biotech Stock Roundup: Amgen Reports Q2, GILD's CAR T Therapy Gets Approval & More

by Zacks Equity Research

The biotech sector remains in focus with earnings, regulatory and other pipeline updates.